These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19785667)

  • 1. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients.
    Cesari M; Caramma I; Antinori S; Adorni F; Galli M; Milazzo L
    HIV Med; 2009 Oct; 10(9):580-5. PubMed ID: 19785667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
    del Valle J; Mira JA; de los Santos I; López-Cortés LF; Merino D; Rivero A; Girón JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Pineda JA
    AIDS; 2008 May; 22(8):923-30. PubMed ID: 18453851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
    Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
    Ryan P; Resino S; Miralles P; Cosín J; López JC; Moreno S; Catalán P; Ramírez M; Gutiérrez I; Berenguer J
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):176-81. PubMed ID: 20577091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M
    Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
    Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
    Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study.
    Cacoub P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Pol S; Halfon P
    Antivir Ther; 2009; 14(6):839-45. PubMed ID: 19812446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.
    Butt AA; Umbleja T; Andersen JW; Sherman KE; Chung RT;
    Clin Infect Dis; 2012 Sep; 55(5):631-8. PubMed ID: 22563020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients.
    Valerio L; Yazdanpanah Y; Poizot-Martin I; Rosenthal E; Marimoutou C; Gastaut JA; Tran A; Dellamonica P; Freedberg KA; Pradier C
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):50-5. PubMed ID: 18156991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
    Merchante N; de los Santos-Gil I; Merino D; González-Serrano M; Mira JA; Sanz-Sanz J; Fernández-Fuertes E; Ruiz-Morales J; del Valle J; Macías J; Moro A; Pineda JA
    J Hepatol; 2009 Apr; 50(4):684-92. PubMed ID: 19231001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.
    Nasta P; Gatti F; Puoti M; Cologni G; Bergamaschi V; Borghi F; Matti A; Ricci A; Carosi G
    AIDS; 2008 Apr; 22(7):857-61. PubMed ID: 18427204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
    Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
    Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
    Nattermann J; Vogel M; Berg T; Danta M; Axel B; Mayr C; Bruno R; Tural C; Klausen G; Clotet B; Lutz T; Grünhage F; Rausch M; Nischalke HD; Schewe K; Bienek B; Haerter G; Sauerbruch T; Rockstroh JK; Spengler U;
    Hepatology; 2007 Oct; 46(4):1016-25. PubMed ID: 17668881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.